Centoxin.
Centoxin is one of a new group of immunotherapeutic agents manufactured from 'humanized' antibodies produced using monoclonal antibody technology. It is indicated in the management of patients with Gram-negative septicaemia; its introduction represents a new approach to treatment in these patients (Luce, 1987).
Davidson
J
J
Department of Paediatrics, University of Birmingham.
Tarlow
M
M
D000911:Antibodies, Monoclonal / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D016470:Bacteremia / Q000628:therapy; D016905:Gram-Negative Bacterial Infections / Q000628:therapy; D006801:Humans; D007075:Immunoglobulin M; D007262:Infusions, Intravenous
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007075:Immunoglobulin M; C068069:nebacumab